Evoke Pharma Q2 net product sales up 47% YoY to $3.8M; reaffirms FY 2025 guidance of ~$16M

Evoke Pharma Inc

2025-Q2 EPS reported -$1.13 revenue$6,832,300

Q2 2025 net product sales $3.8M vs $2.6M in Q2 2024, a 47% increase.
Net loss of $1.6M ($0.62 per share) vs net loss of $1.3M ($0.93 per share) in Q2 2024.
New prescribers grew 20% year-over-year; refill rates steady at ~70%.
Cash and equivalents $12.1M at June 30, 2025; cash runway into Q3 2026.
Full-year 2025 net product sales guidance reaffirmed at approximately $16M, up to 60% over 2024.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.